宁波三星医疗电气股份有限公司 对外投资管理制度 第一章 总则 第一条 为规范宁波三星医疗电气股份有限公司（以下简称"公司"）的对 外投资行为，提高投资效益，规避投资所带来的风险，有效、合理的使用资金， 使资金的时间价值最大化，依照《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上海证 券交易所股票上市规则》、《上海证券交易所上市公司自律监管指引第5号—— 交易与关联交易》等以及其他国家法律、法规的相关规定，结合公司章程、股东 会议事规则、董事会议事规则等公司制度，制定本制度。 第二条 本制度所称的对外投资是指公司为获取未来收益而将一定数量的 货币资金、股权、以及经评估后的实物或无形资产作价出资，对外进行各种形式 的投资活动。 第三条 按照投资期限的长短，公司对外投资分为短期投资和长期投资。短 期投资主要指公司购入的能随时变现且持有时间不超过一年（含一年）的投资， 包括各种股票、债券、基金、分红型保险等； 长期投资主要指投资期限超过一年，不能随时变现或不准备变现的各种投 资，包括债券投资、股权投资和其他投资等。包括但不限于下列类型： （一）公司独立兴办 ...

宁波三星医疗电气股份有限公司 章程 2025 年 4 月 | 第一章 | 总 则 2 | | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股 份 3 | | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 | 4 | | 第三节 | 股份转让 | 5 | | 第四章 | 股东和股东大会 | 6 | | 第一节 | 股东 | 6 | | 第二节 | 股东大会的一般规定 | 8 | | 第三节 | 股东大会的召集 | 11 | | 第四节 | 股东大会的提案与通知 | 13 | | 第五节 | 股东大会的召开 | 14 | | 第六节 | 股东大会的表决和决议 | 17 | | 第五章 | 董事会 22 | | | 第一节 | 董事 | 22 | | 第二节 | 董事会 | 24 | | 第六章 | 总裁及其他高级管理人员 | 28 | | 第七章 | 监事会 30 | | | 第一节 | 监事 | 30 | | 第二节 | 监事会 | 31 | | 第八章 | 财务会计制度、利润分配和审计 | 32 | | 第一节 | 财务会计制度 ...

宁波三星医疗电气股份有限公司 2024年度独立董事述职报告（段逸超） 各位董事： 作为宁波三星医疗电气股份有限公司（以下简称"公司"）的独立董事，本 着对公司全体股东负责的态度，2024年度本人严格按照《公司法》、《证券法》、 《上市公司治理准则》、《上市公司独立董事管理办法》等有关法律法规及《公 司章程》、《独立董事工作细则》及《独立董事年报工作制度》的规定和要求， 勤勉尽责地履行独立董事的职责和义务，审慎认真地行使公司和股东所赋予的权 利，积极参加公司股东会、董事会及各专门委员会会议，为公司的长远发展积极 出谋划策，对董事会的科学决策和规范运作以及公司内部控制起到了积极作用， 现将我在2024年度的工作情况报告如下： 一、独立董事的基本情况 段逸超：男，中国国籍，1963年出生，硕士学历，律师，曾任宁波开发区律 师事务所律师、主任，浙江和义律师事务所律师、副主任，浙江康派律师事务所 律师、主任，曾兼任宁波市人大常委会法工委委员，海伦钢琴股份有限公司、宁 波理工环境能源科技股份有限公司独立董事。现任浙江和义观达律师事务所律 师、合伙人，现兼任球冠电缆股份有限公司独立董事。 （二）是否存在影响独立性的情况说明 ...

宁波三星医疗电气股份有限公司 2024年度独立董事述职报告（王溪红） 各位董事： 作为宁波三星医疗电气股份有限公司（以下简称"公司"）的独立董事，本 着对公司全体股东负责的态度，2024年度本人严格按照《公司法》、《证券法》、 《上市公司治理准则》、《上市公司独立董事管理办法》等有关法律法规及《公 司章程》、《独立董事工作细则》及《独立董事年报工作制度》的规定和要求， 勤勉尽责地履行独立董事的职责和义务，审慎认真地行使公司和股东所赋予的权 利，积极参加公司股东会、董事会及各专门委员会会议，为公司的长远发展积极 出谋划策，对董事会的科学决策和规范运作以及公司内部控制起到了积极作用， 现将我在2024年度的工作情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 王溪红：女，中国国籍，1975年出生，硕士研究生学历；中国注册会计师、 中国注册税务师；浙江省优秀注册会计师、宁波会计行业领军人才、中国注册税 务师协会高端人才。现任宁波正源税务师事务所、宁波正源会计师事务所、宁波 正源企业管理咨询有限公司副总经理。同时兼任乐歌股份、恒帅股份独立董事。 （二）是否存在影响独立性的情况说明 本人 ...

宁波三星医疗电气股份有限公司 2024年度独立董事述职报告（杨华军-已离任） 各位董事： 作为宁波三星医疗电气股份有限公司（以下简称"公司"）的独立董事，本 着对公司全体股东负责的态度，2024年度本人严格按照《公司法》、《证券法》、 《上市公司治理准则》、《上市公司独立董事管理办法》等有关法律法规及《公 司章程》、《独立董事工作细则》及《独立董事年报工作制度》的规定和要求， 勤勉尽责地履行独立董事的职责和义务，审慎认真地行使公司和股东所赋予的权 利，积极参加公司股东会、董事会及各专门委员会会议，为公司的长远发展积极 出谋划策，对董事会的科学决策和规范运作以及公司内部控制起到了积极作用， 现将我在2024年度的工作情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 杨华军：男，中国国籍，1976年出生，博士学历，工商管理（会计学）副教 授，曾任海通证券宁波营业部项目经理。现任浙江万里学院副教授，同时兼任永 泰运化工物流股份有限公司、广博集团股份有限公司、荣安地产股份有限公司独 立董事，宁波名山建设发展集团有限公司董事，宁波布里斯特园艺制品有限公司 监事，北京炜衡（宁波）律师事务所 ...

Dividend Distribution - The company plans to distribute a cash dividend of 8.90 RMB per 10 shares, totaling approximately 1,245,551,287.81 RMB, which accounts for 55.12% of the net profit attributable to shareholders for the fiscal year 2024[4]. - The total amount for cash dividends and share repurchases is projected to be 1,472,267,330.21 RMB, representing 65.16% of the net profit attributable to shareholders for 2024[4]. - The total share capital eligible for profit distribution is 1,399,495,829 shares after excluding repurchased shares[4]. - The proposed cash dividend for 2024 is RMB 1,245,551,287.81, representing 55.12% of the projected net profit attributable to shareholders[163]. - The total cash dividends distributed over the last three accounting years amount to RMB 2,649,775,516.51[168]. - The average net profit over the last three accounting years is RMB 1,703,778,489.64, resulting in a cash dividend ratio of 155.52%[169]. - The company has implemented a cash dividend policy in accordance with regulatory guidelines since 2013[161]. - The company ensures that minority shareholders have opportunities to express their opinions and that their rights are protected[164]. Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 15%[13]. - The company's operating revenue for 2024 reached ¥14.60 billion, representing a 27.38% increase compared to ¥11.46 billion in 2023[20]. - Net profit attributable to shareholders for 2024 was ¥2.26 billion, an 18.69% increase from ¥1.90 billion in 2023[20]. - The basic earnings per share for 2024 was ¥1.60, up 18.52% from ¥1.35 in 2023[21]. - The weighted average return on equity increased to 19.62% in 2024, up from 18.51% in 2023, marking an increase of 1.11 percentage points[21]. - The total assets of the company at the end of 2024 were ¥24.48 billion, a 13.78% increase from ¥21.51 billion at the end of 2023[20]. - The net cash flow from operating activities for 2024 was ¥1.84 billion, a slight decrease of 3.43% from ¥1.90 billion in 2023[20]. - The company achieved operating revenue of 14.6 billion yuan, a year-on-year increase of 27.38%, and a net profit attributable to shareholders of 2.26 billion yuan, up 18.69% year-on-year[33]. Market Expansion and Growth Strategy - The company projects a revenue growth of 20% for the next fiscal year, aiming for 1.44 billion RMB[13]. - The company is expanding its market presence by entering three new provinces, targeting a 10% market share in these regions within two years[13]. - Recent acquisitions include a strategic purchase of a local competitor for 300 million RMB, enhancing the company's service capabilities[13]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20]. - The company is focusing on high-end markets and has made significant breakthroughs in Europe and Latin America, including securing a 466 million yuan transformer project in Greece[38]. Research and Development - The company is investing 50 million RMB in R&D for innovative technologies in medical equipment[13]. - The company’s R&D expenses amounted to 523.33 million RMB, reflecting an increase of 11.15% year-on-year[72]. - The company has filed for 37 invention patents, 117 utility model patents, and 45 design patents in the smart power distribution sector for 2024[40]. - The company has obtained 32 automation patents in the past three years, continuing to advance its "smart manufacturing" strategy[64]. Operational Efficiency and Cost Management - The company has implemented cost-cutting measures projected to save 100 million RMB annually, improving overall profitability[13]. - The company reported a 25% reduction in operational costs due to efficiency improvements implemented in Q3 2023[138]. - The introduction of AI algorithms and APS integration has accelerated delivery times by approximately 20%[64]. - The company has invested over 200 million RMB in automation, significantly improving efficiency[63]. Healthcare and Rehabilitation Services - The company expanded its rehabilitation medical service chain by adding 10 new hospitals, including 1 acquisition and 9 self-built facilities, bringing the total to 38 hospitals with over 10,000 beds[42]. - The company established 4 respiratory weaning centers and 3 consciousness recovery centers, enhancing its specialized treatment capabilities in critical rehabilitation[43]. - The company’s internet medical services achieved over 5,000 annual consultations with a satisfaction score of 99, reflecting significant improvements in service quality[44]. - The company is focusing on the rehabilitation medical industry, enhancing its strategic layout in the healthcare sector to improve hospital operational efficiency and quality[112]. Environmental and Social Responsibility - The company has invested 9.54 million yuan in environmental protection during the reporting period[179]. - The company reduced carbon emissions by 12,108.19 tons through various measures, including rooftop solar power usage and energy-saving modifications[188]. - The company has established a robust internal control system that meets management and development needs, ensuring the interests of all shareholders[175]. - The company donated air conditioning units worth 67,500 RMB to Jiangxi Technician College, reflecting its commitment to social responsibility[190]. Corporate Governance and Compliance - The company has conducted five shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[123]. - The company reported no significant differences in governance compared to regulations set by the China Securities Regulatory Commission[130]. - The company has implemented measures to ensure the independence of its operations from controlling shareholders[130]. - The company is committed to sustainable development practices, as evidenced by its recognition in the "2024 Sustainable Development Best Practice" category[130]. Investment and Financial Commitments - The company has committed to achieving a net profit of no less than 24.6 million yuan from 2022 to 2024, with compensation in cash if not met[194]. - The performance commitments include provisions for cash compensation based on shareholding ratios in case of unmet targets[194][195]. - The company is actively managing its investment partnerships to ensure alignment with financial performance targets and regulatory compliance[194][195]. - The company has completed significant equity investments in rehabilitation medical facilities, totaling approximately RMB 67.44 million, with a total loss impact of RMB -1.38 million for the period[102][103].

Financial Performance - The company's operating revenue for Q1 2025 reached ¥3,630,793,866.31, representing a year-over-year increase of 20.03% compared to ¥3,024,788,914.34 in the same period last year[3]. - Net profit attributable to shareholders was ¥489,308,019.24, a 34.33% increase from ¥364,254,826.35 in the previous year[3]. - The basic earnings per share (EPS) increased to ¥0.35, up 34.62% from ¥0.26 in the same period last year[3]. - Operating profit for Q1 2025 was ¥567,140,535.34, up 31.0% from ¥432,786,545.03 in Q1 2024[20]. - Net profit attributable to shareholders for Q1 2025 was ¥489,308,019.24, representing a 34.4% increase compared to ¥364,254,826.35 in Q1 2024[20]. - The company reported a total comprehensive income of ¥494,688,231.23 for Q1 2025, an increase from ¥364,574,945.30 in Q1 2024[20]. - The company's revenue for Q1 2025 reached ¥543.27 million, a 22.5% increase compared to ¥443.46 million in Q1 2024[29]. - Operating profit for Q1 2025 was ¥131.69 million, up 46.6% from ¥89.78 million in Q1 2024[29]. - Net profit for Q1 2025 was ¥121.29 million, representing a 38.8% increase from ¥87.39 million in Q1 2024[30]. - The total comprehensive income for Q1 2025 was ¥79.54 million, compared to ¥72.07 million in Q1 2024[30]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.09, up from ¥0.06 in Q1 2024[30]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥148,434,278.48, a decline of 149.41% compared to a positive cash flow of ¥99,347,382.01 in the previous year[3]. - Cash inflow from operating activities for Q1 2025 was CNY 3,034,317,675.10, an increase of 5.64% compared to CNY 2,872,763,896.15 in Q1 2024[23]. - Cash flow from operating activities for Q1 2025 was ¥32.65 million, a decrease of 62% compared to ¥86.08 million in Q1 2024[31]. - The company's cash and cash equivalents decreased to RMB 3.934 billion from RMB 4.539 billion[14]. - Cash and cash equivalents at the end of Q1 2025 were CNY 3,597,433,814.31, down from CNY 4,754,411,811.83 in Q1 2024[24]. - The company's cash and cash equivalents at the end of Q1 2025 were ¥633.92 million, down from ¥2.89 billion at the end of Q1 2024[32]. - The total non-current assets increased to RMB 10.877 billion from RMB 10.677 billion[15]. - The total assets of the company stood at RMB 24.530 billion, a slight increase from RMB 24.476 billion[15]. - Total assets increased to CNY 14,462,952,415.77 as of March 31, 2025, from CNY 12,932,806,743.68 a year earlier[27]. Liabilities and Equity - Total liabilities decreased to ¥11,721,971,014.71 in Q1 2025 from ¥12,202,548,432.10 in Q1 2024, a reduction of 3.9%[19]. - Total equity increased to ¥12,808,249,649.14 in Q1 2025 from ¥12,273,938,154.83 in Q1 2024, reflecting a growth of 4.4%[19]. - Total liabilities rose to CNY 5,838,070,368.35 in Q1 2025, compared to CNY 4,390,923,329.33 in Q1 2024[28]. - Shareholders' equity increased to CNY 8,624,882,047.42 in Q1 2025, up from CNY 8,541,883,414.35 in Q1 2024[28]. - The equity attributable to shareholders increased to ¥12,590,896,965.13, reflecting a growth of 4.21% from ¥12,081,698,336.27 at the end of the previous year[4]. Operational Highlights - The company reported a significant increase in net profit primarily due to growth in operating revenue and increased foreign exchange gains[7]. - The company experienced a substantial increase in material payment costs, impacting the net cash flow from operating activities negatively[7]. - The company reported a total order backlog of RMB 15.717 billion, representing a year-over-year increase of 26.12%[11]. - The overseas distribution order backlog reached RMB 1.667 billion, showing a significant year-over-year growth of 134.05%[11]. - The company continues to focus on expanding its market presence and enhancing its product offerings[11]. - Research and development expenses for Q1 2025 were ¥117,042,069.26, up 8.5% from ¥107,606,619.48 in Q1 2024[19]. - Research and development expenses increased to ¥24.18 million in Q1 2025, up 19.7% from ¥20.21 million in Q1 2024[29]. Non-Recurring Items - Non-recurring gains and losses totaled ¥29,169,695.13, with government subsidies contributing ¥16,438,417.99 to this figure[5]. - The financial expenses for Q1 2025 showed a significant improvement, with a net income of -¥46,317,353.47 compared to a cost of ¥18,471,113.41 in Q1 2024[19].

关于 2025 年度预计日常关联交易的公告 证券代码：601567 证券简称：三星医疗 公告编号：临 2025-025 宁波三星医疗电气股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、日常关联交易基本情况 重要内容提示: （一）日常关联交易履行的审议程序 宁波三星医疗电气股份有限公司（以下简称"公司"）于2025年4月24日召开公 司第六届董事会第二十一次会议、第六届监事会第十七次会议，审议通过了《关于 2025年度预计日常关联交易的议案》，其中关联董事已回避表决，该议案已经独立 董事专门会议审议通过。 （二）2024年度日常关联交易的执行情况 单位：万元 | | | 年预 2024 | 年实 2024 | 预计金额 与实际发 | | | --- | --- | --- | --- | --- | --- | | 关联交易 | | | | | | | 类别 | 关联方 | 计发生金 | 际发生金 | 生金额差 | | | | | 额 | 额 | 异较大的 | | | | | | | 原因 | | | 采购商品 ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-024 宁波三星医疗电气股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 被担保人名称 本次预计担保金额及已实际为其担保的余额 本次预计对外提供担保合计总额不超过 974,850 万元，截至本公告披露日，已实 际为上述被担保人提供的担保余额为 560,785.82 万元。 本次是否有反担保：无 1、宁波三星智能电气有限公司 2、宁波明州医院有限公司 3、宁波三星电力发展有限公司 4、NANSEN INSTRUMENTOS DE PRECISÃO LTDA. 5、宁波明州康复医疗投资管理有限公司 6、EasyMeter GmbH 7、NANSEN COLOMBIA S.A.S. 8、NANSEN PERU S.A.C. 9、Sanxing Smart Electric Bangladesh Co. Ltd 10、宁波奥克斯智能科技股份有限公司 11、宁波奥克斯甬能进出口有限公司 12、宁波奥克斯甬能科技 ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-029 宁波三星医疗电气股份有限公司 关于公司变更注册资本、增加经营范围、修订《公司章程》 并办理工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波三星医疗电气股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第六届董事会第二十一次会议，审议通过了《关于公司变更注册资本、增 加经营范围、修订<公司章程>并办理工商变更登记的议案》。 二、增加经营范围情况 根据公司经营发展需要，拟对经营范围进行变更，具体变更经营范围以最终 工商登记机关核定为准。公司拟变更经营范围相关情况如下： 变更前的经营范围：一般项目：以自有资金从事投资活动；医院管理；工程 管理服务；仪器仪表制造；仪器仪表销售；仪器仪表修理；电工仪器仪表制造； 电工仪器仪表销售；供应用仪器仪表制造；供应用仪器仪表销售；机械电气设备 制造；机械电气设备销售；通用零部件制造；电力设施器材制造；电力设施器材 销售；电子元器件制造；电子元器件批发；电子元器件零售；有色金属合金 ...